Expert Ratings for Sutro Biopharma
Over the past 3 months, 6 analysts have published their opinion on Sutro Biopharma (NASDAQ:STRO) stock. These analysts…
Where Sutro Biopharma Stands With Analysts
Sutro Biopharma (NASDAQ:STRO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Sutro Biopharma Earlier Announced Luvelta Demonstrated Encouraging Preliminary Anti-Tumor Activity (29% Response Rate) In Late-stage Patients With Recurrent/relapsed Endometrial Cancer With Tumor Proportion Score (TPS) >25% Folrα Expression
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced initial results from a Phase 1
Sutro Demonstrates Meaningful ADC Innovation With Five Presentations And One Poster At The 14th Annual World ADC Conference
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five
Sutro Biopharma’s Lead Ovarian Cancer Candidate Is A Game Changer, Analyst Sees Huge Upside
Oppenheimer initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO), representing around 200% potential upside.
Benzinga’s Top Ratings Upgrades, Downgrades For October 6, 2023
Upgrades According to B of A Securities, the prior rating for Clearway Energy Inc (NYSE:CWEN) was changed from…
5 Analysts Have This to Say About Sutro Biopharma
Within the last quarter, Sutro Biopharma (NASDAQ:STRO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Stocks That Hit 52-Week Lows On Thursday
During the session on Thursday, 461 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 275 companies made new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
During the Friday's sesion, 157 stocks hit new 52-week lows.